OSE Immunotherapeutics leverages its expertise in the selection and optimization of small proteins called peptides (epitopes or neo-epitopes) to deliver a rationally designed combination of multiple peptides with beneficial therapeutic potential.

The Company uses knowledge and expertise generated from its Memopi ® epitope (neo-epitope) optimization technology a combination of antitumor neo-epitopes to increase the memory immune response of T lymphocytes against specific antigens.

This expertise and technology were recently successfully validated in the Step 1 of the Phase 3 clinical testing for Tedopi® in non-small cell lung cancer and provide the basis for the development program of CoVepiT, a COVID-19 vaccine.